These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 27882107)

  • 1. Effects of sitagliptin as initial therapy in newly diagnosed elderly type 2 diabetics: A randomized controlled study.
    Xiao X; Cui X; Zhang J; Han Z; Xiao Y; Chen N; Li B; Cheng M; Gao H; Tang K
    Exp Ther Med; 2016 Nov; 12(5):3002-3008. PubMed ID: 27882107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Characteristics of glycemic excursion in different subtypes of impaired glucose intolerance].
    Kang Y; Lu JM; Sun JF; Li CL; Wang XL; Zhang XQ; Lü ZH; Dou JT; Mu YM
    Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(10):669-72. PubMed ID: 19595059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of therapeutic effects between sitagliptin and voglibose both combined with sensor-augmented insulin pump in newly diagnosed type 2 diabetes].
    Shi CH; Wang L; Bai R; Wang YB; Liu D; Zhang XY; Wang H; Yang Y; Du JL
    Zhonghua Yi Xue Za Zhi; 2016 Aug; 96(32):2554-8. PubMed ID: 27596550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose.
    Vardarli I; Arndt E; Deacon CF; Holst JJ; Nauck MA
    Diabetes; 2014 Feb; 63(2):663-74. PubMed ID: 24186866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.
    Murai K; Katsuno T; Miyagawa J; Matsuo T; Ochi F; Tokuda M; Kusunoki Y; Miuchi M; Namba M
    Drugs R D; 2014 Dec; 14(4):301-8. PubMed ID: 25420579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of acarbose and siglitine on blood glucose fluctuation and islet β-cell function in patients with type 2 diabetes mellitus.
    Wang RR; Lv ZM; Dan YP; Chen KY; Zhang C
    J Biol Regul Homeost Agents; 2019; 33(2):365-374. PubMed ID: 30972995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
    Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
    Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.
    Wu T; Ma J; Bound MJ; Checklin H; Deacon CF; Jones KL; Horowitz M; Rayner CK
    Diabetes; 2014 Aug; 63(8):2776-87. PubMed ID: 24647737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial.
    Kondo Y; Harada N; Hamasaki A; Kaneko S; Yasuda K; Ogawa E; Harashima S; Yoneda H; Fujita Y; Kitano N; Nakamura Y; Matsuo F; Shinji M; Hinotsu S; Nakayama T; Inagaki N;
    Diabetol Metab Syndr; 2016; 8():15. PubMed ID: 26925169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between glucose variability evaluated by continuous glucose monitoring and clinical factors, including glucagon-stimulated insulin secretion in patients with type 2 diabetes.
    Ohara M; Hiromura M; Nagaike H; Kohata Y; Fujikawa T; Goto S; Sato N; Kushima H; Terasaki M; Yamamoto T; Mori Y; Hayashi T; Fukui T; Yamagishi SI; Hirano T
    Diabetes Res Clin Pract; 2019 Dec; 158():107904. PubMed ID: 31672500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus.
    Yang HK; Kang B; Lee SH; Kim HS; Yoon KH; Cha BY; Cho JH
    Diabetes Metab J; 2015 Aug; 39(4):335-41. PubMed ID: 26301196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of single-dose DPP-4 inhibitor sitagliptin on β-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naïve, well-controlled type 2 diabetes subjects.
    Alsalim W; Göransson O; Carr RD; Bizzotto R; Tura A; Pacini G; Mari A; Ahrén B
    Diabetes Obes Metab; 2018 Apr; 20(4):1080-1085. PubMed ID: 29227575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose acarbose decreased glucose-dependent insulinotropic peptide and glucagon levels in Chinese patients with newly diagnosed type 2 diabetes mellitus after a mixed meal.
    Chen Z; Fu X; Kuang J; Chen J; Chen H; Pei J; Yang H
    BMC Endocr Disord; 2016 Sep; 16(1):55. PubMed ID: 27686734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
    Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
    Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
    DeFronzo RA; Okerson T; Viswanathan P; Guan X; Holcombe JH; MacConell L
    Curr Med Res Opin; 2008 Oct; 24(10):2943-52. PubMed ID: 18786299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
    Aulinger BA; Bedorf A; Kutscherauer G; de Heer J; Holst JJ; Göke B; Schirra J
    Diabetes; 2014 Mar; 63(3):1079-92. PubMed ID: 24296715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study.
    Schopman JE; Hoekstra JBL; Frier BM; Ackermans MT; de Sonnaville JJJ; Stades AM; Zwertbroek R; Hartmann B; Holst JJ; Knop FK; Holleman F
    Diabetes Obes Metab; 2015 Jun; 17(6):546-553. PubMed ID: 25694217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different effects of two dipeptidyl peptidase-4 inhibitors and glimepiride on β-cell function in a newly designed two-step hyperglycemic clamp.
    Zhang Y; Chi J; Wang W; Hong J; Gu W; Wang B; Ning G
    J Diabetes; 2015 Mar; 7(2):213-21. PubMed ID: 24889731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.